TABLE 2

Patient Characteristics (n = 46)

CharacteristicData
Age (y)80 ± 8 (53–90)
Time since diagnosis of prostate cancer (y)8 ± 6 (2–26)
PSA (ng/mL)396 ± 674 (0.06–3,129)
Gleason score at diagnosis*
 <89/41 (22%)
 ≥832/41 (78%)
Sites of metastatic disease
 Bone44/46 (96%)
 Lymph node33/46 (72%)
 Visceral sites†15/46 (15%)
Pattern of bone involvement‡
 None2/46 (4%)
 Oligometastatic (≤3)4/46 (9%)
 Disseminated (>3)33/46 (72%)
 Diffuse bone marrow involvement7/46 (15%)
Previous treatment
 Prostatectomy26/46 (57%)
 Radiotherapy to prostate/prostate bed33/46 (72%)
 ADT46/46 (100%)
 Abiraterone29/46 (63%)
 Enzalutamide15/46 (33%)
 Docetaxel28/46 (61%)
 Cabazitaxel5/46 (11%)
 223Ra-dichloride7/46 (15%)

  • ↵* Unknown in 5 cases.

  • ↵† Lung (n = 8); pleura (n = 3); peritoneal carcinomatosis (n = 2, adrenal gland (n = 1); liver (n = 1).

  • ↵‡ According to PROMISE (1).

  • ADT = androgen deprivation therapy.

  • Qualitative data are frequency and percentage; continuous data are mean ± SD and range.